Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) was the target of a significant increase in short interest during the month of March. As of March 13th, there was short interest totalling 3,990,100 shares, an increase of 425.8% from the February 27th total of 758,900 shares. Based on an average daily trading volume, of 4,986,700 shares, the short-interest ratio is currently 0.8 days. Currently, 6.2% of the company’s stock are short sold.
Shares of NASDAQ TRIL opened at $3.95 on Friday. The business’s 50 day moving average price is $4.30 and its two-hundred day moving average price is $1.81. The company has a market cap of $327.00 million, a PE ratio of -2.82 and a beta of 2.28. Trillium Therapeutics has a twelve month low of $0.24 and a twelve month high of $7.97.
A hedge fund recently bought a new stake in Trillium Therapeutics stock. Jane Street Group LLC bought a new position in shares of Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 28,588 shares of the biotechnology company’s stock, valued at approximately $29,000. Jane Street Group LLC owned 0.10% of Trillium Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 30.45% of the company’s stock.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.